



**HAL**  
open science

## Stage-specific IFN-induced and IFN gene expression reveal convergence of type I and type II IFN and highlight their role in both acute and chronic stage of pathogenic SIV infection

Nadia Echebli, Nicolas Tchitchek, Stéphanie Dupuy, Timothée Bruel, Caroline Passaes, Nathalie Bosquet, Roger Le Grand, Christine Bourgeois, Benoît Favier, Rémi Cheynier, et al.

### ► To cite this version:

Nadia Echebli, Nicolas Tchitchek, Stéphanie Dupuy, Timothée Bruel, Caroline Passaes, et al.. Stage-specific IFN-induced and IFN gene expression reveal convergence of type I and type II IFN and highlight their role in both acute and chronic stage of pathogenic SIV infection. PLoS ONE, 2018, 13 (1), pp.e0190334. 10.1371/journal.pone.0190334 . pasteur-02861901

**HAL Id: pasteur-02861901**

**<https://pasteur.hal.science/pasteur-02861901>**

Submitted on 9 Jun 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

RESEARCH ARTICLE

# Stage-specific IFN-induced and IFN gene expression reveal convergence of type I and type II IFN and highlight their role in both acute and chronic stage of pathogenic SIV infection

Nadia Echebli<sup>1</sup>, Nicolas Tchitchek<sup>1</sup>, Stéphanie Dupuy<sup>1#a</sup>, Timothée Bruel<sup>1#b</sup>, Caroline Peireira Bittencourt Passaes<sup>1#c</sup>, Nathalie Bosquet<sup>1</sup>, Roger Le Grand<sup>1</sup>, Christine Bourgeois<sup>1</sup>, Benoit Favier<sup>1</sup>, Rémi Cheyner<sup>2,3,4</sup>, Olivier Lambotte<sup>1,5</sup>, Bruno Vaslin<sup>1\*</sup>

**1** CEA, Université Paris Sud, INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases (IMVA), IDMIT Department / IBFJ, Fontenay-aux-Roses, France, **2** Cytokines and Viral Infections, Immunology Infection and Inflammation Department, Institut Cochin, INSERM U1016, Paris, France, **3** CNRS, UMR8104, Paris, France, **4** Université Paris Descartes, Paris, France, **5** APHP, Service de Médecine Interne–Immunologie Clinique, Hôpitaux Universitaires Paris Sud, Le Kremlin-Bicêtre, France

#a Current address: Université Paris Descartes, CICB, Paris, France

#b Current address: Institut Pasteur, Department of Virology, Paris, France

#c Current address: Institut Pasteur, HIV, Inflammation and Persistence Unit, Paris, France

\* [bruno.vaslin@cea.fr](mailto:bruno.vaslin@cea.fr)



**OPEN ACCESS**

**Citation:** Echebli N, Tchitchek N, Dupuy S, Bruel T, Peireira Bittencourt Passaes C, Bosquet N, et al. (2018) Stage-specific IFN-induced and IFN gene expression reveal convergence of type I and type II IFN and highlight their role in both acute and chronic stage of pathogenic SIV infection. PLoS ONE 13(1): e0190334. <https://doi.org/10.1371/journal.pone.0190334>

**Editor:** Cristian Apetrei, University of Pittsburgh Centre for Vaccine Research, UNITED STATES

**Received:** September 26, 2017

**Accepted:** December 12, 2017

**Published:** January 11, 2018

**Copyright:** © 2018 Echebli et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** Raw and normalized microarray expression data are publicly available on the ArrayExpress database (ID: E-MTAB-6068).

**Funding:** This work was supported by the Agence Nationale de Recherches sur le SIDA et les hépatites virales ([www.anrs.fr](http://www.anrs.fr)). NE, SD and CPBP benefited from ANRS post-doctoral fellowships. This work was also supported by Agence Nationale de Recherches sur le SIDA et les hépatites virales

## Abstract

Interferons (IFNs) play a major role in controlling viral infections including HIV/SIV infections. Persistent up-regulation of interferon stimulated genes (ISGs) is associated with chronic immune activation and progression in SIV/HIV infections, but the respective contribution of different IFNs is unclear. We analyzed the expression of IFN genes and ISGs in tissues of SIV infected macaques to understand the respective roles of type I and type II IFNs. Both IFN types were induced in lymph nodes during early stage of primary infection and to some extent in rectal biopsies but not in PBMCs. Induction of Type II IFN expression persisted during the chronic phase, in contrast to undetectable induction of type I IFN expression. Global gene expression analysis with a major focus on ISGs revealed that at both acute and chronic infection phases most differentially expressed ISGs were inducible by both type I and type II IFNs and displayed the highest increases, indicating strong convergence and synergy between type I and type II IFNs. The analysis of functional signatures of ISG expression revealed temporal changes in IFN expression patterns identifying phase-specific ISGs. These results suggest that IFN- $\gamma$  strongly contribute to shape ISG upregulation in addition to type I IFN.

(ANRS) through research project grant 11360 attributed to BV, by the agence Nationale de la Recherche (<http://www.agence-nationale-recherche.fr>) "Programme d'Investissements d'Avenir" (PIA) under Grant ANR-11-INBS-0008, that funds the Infectious Disease Models and Innovative Therapies (IDMIT, Fontenay-aux-Roses, France) infrastructure, and PIA grant ANR-10-EQPX-02-01 that funds the FlowCyTech facility (project investigator RLG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

## Introduction

Interferons (IFNs) are among the earliest signaling proteins released by the immune system in response to viral infections [1–3]. IFN signaling through IFN receptors ultimately results in transcriptional activation of genes called interferon-stimulated genes (ISGs) [4–7], which contribute to the induction of a broad antiviral state against a wide range of pathogens in host cells, limiting viral replication and viral spread [8–10]. ISGs restrict viral infection by blocking key steps of viral replication, inducing the death of infected cells [3, 11–13]. They include important modulators of both innate and adaptive immunity [5, 14–16]. ISGs act directly on immune cells, favor their recruitment to inflamed tissues, and contribute to inflammation [14, 17, 18].

Type I IFN (IFN- $\alpha$ , - $\beta$ , - $\omega$ ) and type II IFN (IFN- $\gamma$ ) play important roles in HIV/SIV pathogenesis. Type I IFN genes are in the first line of defense against viral infections, including HIV/SIV [19–22]. Plasmacytoid dendritic cells (pDC) sense RNA viruses, including HIV [23, 24], and are major contributors of IFN- $\alpha$  to combat acute SIV infections [25–27].

IFN- $\gamma$ , the unique type II IFN [2], is mostly produced by activated NK and T cells, participates in the control of acute infections caused by a variety of viruses, limits pathologies associated with viral persistence, and contributes to adaptive immunity and immune regulation [2, 18]. The function of IFN- $\gamma$  in HIV/SIV infections is complex and not completely understood, but chronic activation of HIV-specific T cells results in abundant secretion of this polypeptide in HIV/SIV infections.

Persistent induction of ISG expression in chronic HIV/SIV infections is predictive of progression to pathogenesis [28–30], despite their large array of antiviral activities, and IFNs are suspected to drive pathogenesis *in vivo*. Chronic induction of ISG expression is often attributed to type I IFNs, but they are often below the threshold of detection in the asymptomatic chronic phase of infection [28, 29, 31, 32]. The respective contribution of type I IFNs and IFN- $\gamma$  in the expression of ISGs during chronic infection is still unclear. Although responses to type I IFNs at the early phases of HIV/SIV infection may limit viral replication [22, 33, 34], IFN-associated viral signatures and resistance to type I IFNs have been reported [35]. Most recent studies suggest that type I IFNs may be friends early in infection but foes during the chronic phase [22, 36, 37]. IFN- $\alpha$  expression in acute SIV infection boosts thymic export, but long-term cytokine production leads to premature thymic involution (Dutrieux et al. AIDS, 2014). In addition, acute IFN- $\alpha$  production during primary infection correlates with the activity of indoleamine 2-3-dioxygenase, an immunosuppressive enzyme [31]. IFN- $\gamma$  is also associated with HIV pathogenesis [38]. Expression levels of IFN- $\gamma$ -Induced Protein IP10 (CXCL10) is predictive of progression in HIV/SIV infections [39–41].

The investigation of differences in canonical signaling pathways may offer an informative approach to explore specific transcriptomic signatures of type I IFNs and IFN- $\gamma$ . Type I IFNs bind to the heterodimeric transmembrane receptor IFNAR (IFNAR1 and IFNAR2) [2]. In the canonical signaling pathway of type I IFNs, IFNAR engagement activates JAK1 and TYK2 receptor-associated protein tyrosine kinases, leading to phosphorylation of the latent cytoplasmic signal transducers and activators of transcription (STAT)1 and STAT2, which dimerize and translocate to the nucleus. They assemble with IFN-regulatory factor 9 (IRF9) to form the trimolecular complex called IFN-stimulated gene factor 3 (ISGF3) [42, 43], which binds to consensus DNA sequences known as IFN-stimulated response elements (ISRE) in gene promoters, activating the transcription of ISGs. IFN- $\gamma$  signals through the IFN- $\gamma$  receptor (IFNGR), a heterotetramer of IFN- $\gamma$ -R1 and IFN- $\gamma$ -R2 subunits [44, 45]. Binding triggers the activation of receptor-associated JAK-1 and JAK-2, and subsequent tyrosine phosphorylation of the cytoplasmic tail of the IFN- $\gamma$ -R1 subunits. STAT-1 is recruited to the phosphorylated

IFN- $\gamma$ R1, becomes phosphorylated, forms homodimers which translocate to the nucleus [46], and binds to gamma-activated sequence elements (GAS) within the promoters of more than 250 IFN- $\gamma$ -responsive genes [47].

In this study, we aimed to decipher the respective contributions of type I and type II IFNs to shed light on their respective influence in HIV/SIV infection and pathogenesis. We analyzed IFN and ISG transcriptomic profiles and their associated functional signatures in the cynomolgus macaque (*Macaca fascicularis*) pathogenic model of SIV infection, taking advantage of longitudinal access to blood and lymphoid tissues. We elucidated the respective contribution of type I and type II IFNs in determining ISG expression levels, patterns, and associated functions in both acute and chronic SIV infection, by classifying the ISGs into either type I or type II, based on information obtained from the Interferome database [48] or by using an innovative approach to classify ISGs based on the presence of ISRE or GAS conserved consensus sequences in their respective promoters.

## Materials and methods

### Ethics statement

Six adult male cynomolgus macaques (*Macaca fascicularis*) were imported from Mauritius and housed in the facilities of the “Commissariat à l’Energie Atomique et aux Energies Alternatives” (CEA, Fontenay-aux-Roses, France). Non-human primates (NHP, which includes *M. fascicularis*) are used at the CEA in accordance with French national regulations and under the supervision of national veterinary inspectors (CEA Permit Number A 92-032-02). The CEA complies with the Standards for Human Care and Use of Laboratory Animals of the Office for Laboratory Animal Welfare (OLAW, USA) under OLAW Assurance number #A5826-01. All experimental procedures were conducted according to European Directive 2010/63 (recommendation number 9) on the protection of animals used for scientific purposes. The animals were used under the supervision of the veterinarians in charge of the animal facility. This study was accredited under statement number 12–103, by the ethics committee “Comité d’Ethique en Expérimentation Animale du CEA” registered under number 44 by the French Ministry of Research.

Animals were housed under controlled conditions of humidity, temperature, and light (12-hour light/12-hour dark cycles). Water was available ad libitum. Animals were monitored and fed commercial monkey chow and fruit 1–2 times daily by trained personnel. The macaques were provided with environmental enrichment, including toys, novel foodstuffs, and music, under the supervision of the CEA Animal Welfare Body.

### Animal infection and sample collection

Cynomolgus macaques ( $n = 6$ ) were exposed intravenously to 5,000 AID50 SIVmac251 as previously described [25, 49]. Peripheral Blood Mononuclear Cells (PBMCs), Peripheral Lymph Nodes (PLNs), either axillary or inguinal, and Rectal mucosa Biopsies (RB) were collected longitudinally. Infection, blood sampling and LN and rectal biopsies were collected under general anesthesia by intra-muscular injection of 10 mg/kg ketamine (Rhone-Merieux, Lyon, France). cDNA microarray profiling was performed before infection and at both acute (day 9 post-infection: D9) and chronic phases (month 3 post-infection: M3) of infection.

### Viral RNA and T-cell quantification

Plasma vRNA was assayed as previously described [49, 50]. Absolute T-cell counts were calculated from lymphocyte counts obtained by automated cell counting (Coulter MDII; Coultronics, Villepinte, France) combined with flow cytometry data as previously described [25].

## IFN-I antiviral activity

Type I IFN activity in plasma was measured using a bioassay that assesses the reduction of the cytopathic effects induced by vesicular stomatitis virus in Madin-Darby bovine kidney cells (kindly provided by Dr P. Lebon, Service de virology, Hopital Cochin-Saint-Vincent de Paul, Paris France) as previously described [25].

## RNA extraction and qPCR

Total RNA was isolated from tissues using the RNeasy mini kit (Qiagen), according to the manufacturer's instructions. To avoid genomic DNA contamination, an additional DNase step was included after the RNase-free DNase step (Qiagen), according to the kit recommendations. The quality and quantity of the RNA were determined using a Nanodrop spectrophotometer. The quantitative rev-transcriptase Kit (Qiagen) was used to synthesize cDNA. Quantitative PCR was performed for each sample on a Light-Cycler using SYBERgreen (Roche) and 0.2  $\mu$ l FastStart Taq (Roche) in a final volume of 25  $\mu$ l.

Quantitative RT-PCR was used to assay *IFN- $\gamma$* , *IRF9*, and *MXA* gene expression using primers described in [S1 Table](#). For *IFN- $\gamma$*  and *IRF9*, q-PCR was performed using the following program: 5 min at 94°C, 40 times (15s 94°C; 30 s 56°C, and 30s 68°C), and 10min at 68°C. The amplification of *MXA* was performed under the following conditions: 95°C for 3 min, followed by 50 cycles of (10s 95°C, 30s 58°C, and 45s 72°C). *HPRT* or *GAPDH* gene expression was used to normalize mRNA levels. Detection of a single product was verified by dissociation curve analysis and relative quantities of mRNA calculated using the method described by [51]. Quantitative RT-PCR was used to assay IFN- $\alpha$  and IFN- $\beta$  as described previously [25, 52].

## Transcriptomic profiling

For oligonucleotide array analyses, total RNA was isolated using the RNeasy RNA isolation kit (Qiagen, CA). The quality and quantity of the RNA were determined using a Bioanalyzer 2100 (Agilent technologies). The cRNA was then amplified using the Low Input Quick Amp labeling kit, one color (Agilent technologies). The quantity and quality of cRNA were evaluated by capillary electrophoresis using an Agilent Technologies 2100 Bioanalyzer and NanoDrop ND-1000. Probe labeling and microarray hybridizations were performed as described in the Agilent 60-mer oligo microarray processing protocol (Agilent Technologies, CA). Six hundred ng of each labeled RNA sample was hybridized to Agilent 8X60K rhesus macaque *Macaca Mulatta* custom 8\*60K array (AMADID 045743, Agilent technologies). The Agilent One-Color Microarray-Based Gene Expression Analysis Protocol was followed for hybridization and array washing. Arrays were scanned with an Agilent microarray G2505C scanner and image analysis was performed using Agilent Feature Extraction 11.0.1 Software. Raw images were analyzed using Agilent Feature Extraction software (version 9.5.3.1) and the GE1\_1100\_Jul11 extraction protocol. All arrays were required to pass Agilent QC flags.

## Transcriptomic analysis

Microarray data were processed using R/Bioconductor. Gene expression values were scaled and normalized using the limma package. Differentially expressed genes were identified using two-sample t-tests ( $p < 0.05$ ) and based on a 2-fold-change (FC) threshold. Functional Enrichment analysis was performed using Ingenuity® Pathway Analysis (IPA, version n° 31813283) and the right tailed-Fisher Exact test. P-values were corrected for multiple comparisons using the Benjamini-Hochberg Multiple Testing Correction. Genes were annotated using DAVID Bioinformatics Resources 6.8 (NIAID/NIH, USA).

Raw and normalized microarray expression data are publicly available on the ArrayExpress database (ID: E-MTAB-6068).

## ISG annotations

Differentially expressed interferon-induced genes were annotated using two approaches as described in **S1 Fig**. The first approach was based on the Interferome database (<http://www.interferome.org>) [48], an open-access database of type I, II, and III Interferon-regulated genes collected from analyzing expression datasets of cells and organisms treated with IFNs. We used this database to identify and classify genes depending on their expression following induction by either type I IFN, type II IFN, or both IFN species. We also used a complementary approach in which the genes were annotated depending on the presence of either GAS, ISRE, or both consensus sequence motifs in gene promoters within the 2,000 bp upstream of the 5'UTR after locating them using Geneious software (<http://www.geneious.com/>). This analysis aimed to identify ISG sets downstream of the canonical type I IFN signaling pathway (ISRE ISGs), the canonical type II IFN signaling pathway (GAS ISGs), or both (GAS&ISRE ISGs).

## Statistical analysis

The Student *t*-test, or the Welch's unequal variances *t*-test when the two samples have unequal variances and unequal sample sizes, were used to determine if two sets of data were significantly different from each other. Alternatively, the non-parametric Wilcoxon rank sum test was used when comparing two related samples. A *p* value <0.05 was considered as significant.

## Results


### Viral replication and disease outcome

We investigated the transcriptomic profiles of type I and II IFNs during acute and chronic SIV infection by infecting six cynomolgus macaques with SIV<sub>mac251</sub> and longitudinal sampling post infection (p.i.). Plasma viremia peaked on day 10 p.i. (**Fig 1A**) at a mean of  $4.4 \times 10^7$  vRNA copies/mL ( $4.2 \times 10^7$  to  $9 \times 10^7$ ). Five macaques displayed persistently high plasma viral loads during the chronic phase and a decline in the number of CD4 T cells (**Fig 1B**). Animal #30742 had plasma viral loads below 400 copies/mL during the chronic phase and no significant decline in the number of CD4 T cells, thus behaving as a controller. Viral replication remained persistently high during the chronic phase in 5/6 animals in both tissues analyzed (Rectal mucosa Biopsies-RB and PLNs) (**Fig 1C and 1D**). Viral RNA loads in tissues were not significantly different at D9 and M3 in these macaques, confirming persistently high SIV replication in tissues during the chronic phase. The vRNA load decreased substantially in animal #30742 tissues by M3, even becoming undetectable in the gut, confirming its controller status.

### Transcriptomic profiling of PBMC, PLN, and RB samples

We then examined gene expression profiles in PBMC, PLN, and RB samples longitudinally collected from these animals, before infection and at D9 and M3 p.i., to characterize the molecular signature of SIV infection. We identified genes with significant differential expression from baseline using a two-sample *t*-tests ( $p < 0.05$ ).

Remarkably, we identified many more differentially expressed genes in PLNs and PBMCs than in RBs (**Fig 2A**). Multidimensional scaling revealed strong segregation of the biological conditions (time points and tissues), reflecting large biological differences, as well as the good quality of the gene signatures (**Fig 2B**). We observed the highest segregation between time




**Fig 1. Infection of six cynomolgus macaques with SIVmac251 and establishment of chronic infection.** (A) vRNA load in plasma. (B) Evolution of total CD4 T cell numbers in the blood over time (percentage of baseline). (C) vRNA in RB. (D) vRNA in PLNs. ULD = under the limit of detection. P values are given for non-parametric Wilcoxon rank sum test and was considered significant if  $p < 0.05$ .

<https://doi.org/10.1371/journal.pone.0190334.g001>

points for PLNs. Of 43,604 probes, 1,638 genes were upregulated by more than two-fold in at least one condition. More genes were differentially upregulated in PLNs than in RBs or PBMCs, and more genes were differentially expressed at D9 than at M3 in all tissues (Fig 2C). Functional enrichment analysis revealed that upregulated genes were mainly associated with functions related to infection, immunity, inflammation, canonical pathways related to interferon signaling, and communication between innate and adaptive immune cells at both phases of infection (S2 Fig and S2 Table).

We first analyzed the expression profile of IFNs and their related receptors, as our aim was to elucidate the respective contribution of type I IFNs and IFN- $\gamma$  in ISG induction during acute and chronic SIV infection and their contribution to HIV/SIV pathogenesis. There was higher expression of both type I IFN genes (*IFN- $\alpha$* , *IFN- $\beta$*  and *IFN- $\omega$* ) and IFN- $\gamma$  during primary than chronic infection. The expression of type I IFN genes was mostly similar in PLNs, whereas it was very heterogeneous in the RBs among the macaques (differential expression in only two of six macaques at D9). No change in type I IFN gene expression was observed in PBMC (Fig 2D). *IFN- $\gamma$*  displayed a similar expression pattern as type I IFN genes during the acute phase, although at lower levels, with similar inter-individual disparity in the RB, and no increase in PBMCs. In contrast to type I IFN genes, high *IFN- $\gamma$*  expression was remarkably



**Fig 2. Transcriptome profiling reveals inter-tissue differences and the evolution of differential gene expression post-infection.** Two critical time points, day 9 (D9) and month 3 (M3) p.i., were compared to baseline (before viral infection) (A) Number of genes with significant differential expression relative to baseline in RBs, PLNs, and PBMCs. A two-sample t-tests ( $p < 0.05$ ) was used to identify differentially expressed genes (B) Multidimensional scaling (MDS) representation showing the segregation of biological samples based on the altered expression of the 1,638 genes with FC > 2. (C) Venn diagram showing the distribution of differentially expressed genes over time in RBs, PLNs, and PBMCs. (D) Evolution of RNA expression of interferons and interferon receptors in RBs, PLNs, and PBMCs at D9 and M3 p.i. Heatmap representing the FC from baseline for the six SIVmac251 infected macaques.

<https://doi.org/10.1371/journal.pone.0190334.g002>

persistent in the PLNs during the chronic phase of infection, likely reflecting ongoing persistent chronic T-cell activation reported in this model [25].

We confirmed the transient increase of *IFN- $\alpha$*  and *IFN- $\beta$*  mRNA expression during the acute phase of infection by RT-qPCR (Fig 3A and 3B). The large inter-individual difference in type I IFN gene expression levels in RBs was also confirmed (Fig 3C). We also confirmed the increased expression of *IFN- $\gamma$*  at both D9 and M3 by RT-qPCR (Fig 3D). Microarrays also showed increased ISG expression (S3 Fig) at both time points, confirmed in PLNs by RT-qPCR for *MX1* (Fig 3E) and *IRF9* (Fig 3F). These data also suggested more consistent ISG expression in PLNs than in RB, likely resulting from the disparity of IFN gene expression in this tissue, and, to a lesser extent, than in PBMCs, in which the expression of IFN genes was not significant at any phase of infection. Acute expression of both type I IFNs and *IFN- $\gamma$*  during the primary infection phase was also confirmed at the protein level by measuring the antiviral function of type I IFNs (Fig 3G) and *IFN- $\gamma$*  concentrations in plasma (Fig 3H). During the acute phase, *IFN- $\gamma$*  expression, which is inducible by type I IFNs, strongly correlated with that of type I IFNs in the plasma (Pearson  $R = 0.99$ ,  $p$ -value < 0.0001).


Our data indicate that PLNs are a major source of IFN production and consequent ISG expression in SIV-infected cynomolgus macaques, in accordance with data reported for SIVmac251-infected rhesus macaques [26, 53, 54]. Persistent *IFN- $\gamma$*  expression contrasted with blunted type I IFN gene expression in PLNs during the chronic phase.

## SIVmac251 infection induces both type I and Type II ISGs during both phases of infection in PLNs

We previously showed early trafficking of pDC in PLNs and their contribution to massive *IFN- $\alpha$*  production during acute infection [25, 31]. We focused our ISG analysis on PLNs, because we previously observed that *IFN- $\alpha$*  production is followed by high ISG expression in this tissue, and because IFNs were mainly produced in PLNs in the present study. We excluded the controller macaque #30742 from the data set for ISG analyses to avoid a confounding factor by including an animal with a different disease outcome.

We identified 278 ISGs among 1,638 up-regulated genes in PLNs. A total of 169 ISGs were specifically induced during the acute phase, but not the chronic phase (D9-ISGs), and 58 were specifically induced during the chronic phase, but not the acute phase (M3-ISGs), whereas 51 were induced at both time points (D9&M3-ISGs) (Fig 4A). The transition from the acute to chronic phase of infection was associated with a large decrease in the expression of ISGs of the D9&M3-ISG group ( $p < 0.0001$ , Wilcoxon signed rank test) (Fig 4B, left panel). These genes included apoptotic, activation marker, chemokine/chemokine receptor, interferon regulation, and antiviral genes (Fig 4B, right panel). Nevertheless, the change in expression of D9-ISGs was not significantly different from that of M3-ISGs (data not shown). The main biological functions associated with D9-ISGs and M3-ISGs and their FC are listed in S3 Table.

We annotated the ISGs using the Interferome database [48] to understand the contribution of type I IFNs, type II IFN, or both to the ISG expression pattern and identified type-I ISGs (inducible by type I IFNs but not type II IFN), type II ISGs (inducible by type II IFN but not




**Fig 3. Confirmation of differential expression of IFNs in tissues by RT-qPCR and at the protein level in plasma. (A)** IFN- $\alpha$  mRNA expression in PLNs by RT-qPCR. **(B)** IFN- $\beta$  mRNA expression in PLNs by RTqPCR. **(C)** IFN- $\alpha$  mRNA expression in RB by RT-qPCR. **(D)** IFN- $\gamma$ mRNA expression in PLNs by RT-qPCR. **(E)** MXA mRNA expression in PLNs by

RT-qPCR. (F) IRF9 mRNA expression in PLNs by RT-qPCR. (G) Type-I IFN antiviral activity measured in plasma (MDBK/VSV biological assay) and (H) plasma IFN- $\gamma$  concentration (measured by Luminex). ULD = Under the Limit of Detection. The Lower Limit of Quantification (LLOQ) is represented as a red dotted line in figure 3H. P values are given for non-parametric Wilcoxon rank sum test and was considered significant if  $p < 0.05$ .

<https://doi.org/10.1371/journal.pone.0190334.g003>

type I IFNs), and TypeI&II ISGs (inducible by both IFN species). We also used a novel approach to restrict our analysis to genes directly targeted by interferon signaling and to exclude any genes described in the Interferome database that may be induced by secondary mechanisms. It consisted of annotating the ISGs based on the presence of ISRE and/or GAS consensus sequences in the promoter regions of all ISGs upstream of the 5'UTR, as these sequences are targets of ISGF3 (STAT1/STAT2/IRF9) and STAT1/STAT1 homodimer complexes in the canonical signaling pathways of type I IFNs and type II IFN, respectively.

At D9 p.i. (Fig 4C, left panel), 23 genes belonged to the type I ISG group, whereas three belonged to the type II ISG group. These results suggest that type I IFNs and type II IFN induce the expression of distinct and specific sets of ISGs during the acute phase, but most ISGs upregulated at D9 were inducible by both type I IFNs and type II IFN (194 genes, 88.2%), showing strong convergence of type I IFNs and type II IFN in the induction of ISG expression.



**Fig 4. SIV infection induces ISG expression during both phases of infection in PLNs.** (A) Venn diagram showing the number of ISGs expressed at D9, M3, or both time points. (B) Comparison of mean ISG expression FC at D9 and M3 p.i. for the 51 ISGs expressed at both time points. (C) Venn diagram of ISGs expressed at D9 p.i., splitting them into those only inducible by type I IFN (Type I), only inducible by type II IFN (Type II), and those inducible by both IFN types (left) and comparison of their mean induction levels (right). (D) Venn diagram of ISGs expressed at M3 p.i., splitting them into those only inducible by type I IFN, those only inducible by type II IFN, and those inducible by both IFN types (left) and comparison of their induction levels (right). (E) Venn diagram of ISGs expressed at D9 p.i., splitting them into those displaying at least one ISRE, one GAS, or both sequence motifs in their promoters (left) and comparison of their induction levels (right). (F) Venn diagram of ISGs expressed at M3 p.i., splitting them into those displaying at least one ISRE, one GAS, or both in their promoters (left) and comparison of their induction levels (right). (G) Functional enrichment of type I-, type II-, and type I&II ISG subsets. The p value was calculated by the Fisher test with the Benjamini-Hochberg correction for multiple comparisons. The  $-\log(p\text{-value})$  is given for the most significant processes. In C, D, E, and F, the p value is given for Welch's unequal variances *t*-test, considering  $p < 0.05$  to be significant.

<https://doi.org/10.1371/journal.pone.0190334.g004>

Type I-ISGs showed a higher FC in expression than type II-ISGs at D9 (**Fig 4C, right panel**) and type I&II-ISGs displayed a significantly higher FC in expression than either type I- or type II-ISGs, suggesting strong synergy between type I IFNs and IFN- $\gamma$  during the acute phase ( $p = 0.02$  and  $p = 0.006$ , respectively).

At M3, 30 genes belonged to the type I-ISG group, whereas 12 belonged to the type II-ISG group (**Fig 4D, left panel**), suggesting that type I IFNs and IFN- $\gamma$  also induce the expression of distinct sets of ISGs during the chronic phase of infection. Most ISGs significantly induced at M3 were inducible by both type I IFNs and type II IFN (67 genes, 61.5%), as during the acute phase. These ISGs displayed a significantly higher induction of expression than type I-ISGs ( $p = 0.0022$ ) (**Fig 4D, right panel**). These data show that type I IFNs and IFN- $\gamma$  strongly converge to induce ISG expression during the chronic phase, and suggest that IFN- $\gamma$  strongly contributes to enlarging the repertoire of ISGs expressed during the chronic phase.

We then used the GAS/ISRE annotation to investigate the respective roles of the targeting of these sequences in the signaling pathways leading to ISG expression. During primary infection (**Fig 4E**), 94 of 220 stimulated ISGs displayed at least one GAS and one ISRE upstream of the 5'UTR (42.7%). Additionally, 80 displayed at least one GAS, but no ISRE, and 46 displayed at least one ISRE, but no GAS. The expression of ISRE&GAS-inducible ISGs was more highly induced than ISGs inducible through GAS alone ( $p = 0.0004$ ). These data show that GAS and ISRE signaling pathways induce the expression of distinct ISG subsets (ISRE-inducible ISGs or GAS-inducible ISGs), and converge to induce the expression of GAS&ISRE-inducible ISGs to higher levels than that of ISRE-ISG and GAS-ISG subsets.

In the chronic phase (**Fig 4F**), 31 differentially expressed ISGs belonged to the ISRE-ISG group (33.0%), 34 to the GAS-ISG group (36.2%), and 44 to the ISRE&GAS group (40.4%). The ISRE&GAS-ISGs had, on average, a higher change in expression than the ISRE-ISGs ( $p = 0.0006$ ) or GAS-ISGs ( $p < 0.0001$ ). These data show that both GAS and ISRE signaling pathways are used to induce distinct ISG subsets during the chronic phase of SIV infection and that the expression of GAS&ISRE-ISGs is induced to higher levels than that of ISRE-ISGs or GAS-ISGs. This suggests convergence of the type I IFNs and type II IFN canonical pathways and potential synergy between type I IFNs and IFN- $\gamma$  for the induction of ISG expression.

We then analyzed the biological processes or canonical pathways associated with type-I, type-II, and type-I&II differentially expressed ISG subsets, independently of the time of induction (**Fig 4G**). There was marked enrichment for the three subsets in processes associated with immune responses to infectious disease, including immune-cell trafficking, cell signaling, inflammation, and cell death. Differentially expressed ISGs induced by both type I IFNs and type II IFN (type I&II subset) were much more highly enriched in many immunological functions and inflammation than ISGs only induced by type I IFNs or IFN- $\gamma$ . These data show that type I&II-ISGs are more highly involved in most of these functions than type-I-ISGs or type-II-ISGs.


Overall, our data show strong convergence of type I IFNs and IFN- $\gamma$  in the induction of ISG expression in both the acute and chronic phases of SIV infection, as the expression of most ISGs is inducible by both type I IFN and IFN- $\gamma$  through their respective canonical pathways and show the highest induction.

These ISGs have major functions in inflammation and antiviral responses and represent as much as 88.2% of the upregulated ISGs during the acute phase, when both type I IFNs and IFN- $\gamma$  are strongly upregulated in PLNs, whereas they represent 61.5% of upregulated ISGs in the chronic phase, when IFN- $\gamma$  is still upregulated at high levels, but type I IFNs are undetectable. Convergence between type I IFN and IFN- $\gamma$  was therefore more prominent during the acute than chronic phase, but still played an important role in the induction of ISG expression during the chronic phase.

### The functional signature of ISGs changes during infection


We then analyzed the evolution of the functional signatures of ISGs during infection by comparing their degree of association with biological processes at D9 and M3. The complete list of ISGs, including their FC at each time point and the main functions significantly associated with them, is shown in [S3 Table](#). We then compared three ISG subsets based on their kinetics of induction (ISGs induced only at D9, ISGs only induced at M3, and ISGs induced at both D9 and M3) by Ingenuity Pathway Analysis. The three ISG subsets associated with biological functions with varying strength ([Fig 5](#)). ISGs induced only at D9 and those induced at both time points were most strongly associated with processes related to cell-mediated immune responses, inflammation, cell death, and the innate immune response to infectious diseases, but weakly associated with DNA replication and cell cycle control, whereas those expressed only at M3 were most significantly associated with two specific functions, cell cycle control and DNA replication. ISGs induced at both time points were most significantly associated with the response to infectious diseases, antimicrobial responses, inflammatory responses, cellular immunity, and cell signaling. These data show that the ISG functional signature is dependent on the time of infection, which was confirmed by comparing signatures of all ISGs induced at D9 to those induced at M3 ([S4 Fig](#)).

We more fully studied the functional imprint of ISGs at the gene level by representing the FC in expression of ISGs that were upregulated and signed the most significant functions in clustered heat maps ([Fig 6](#)). They show significant involvement of IFNs in IFN signaling, cell communication (chemokines, cytokines and their receptors), cell activation (both T-cell activation and antigen presenting cells), apoptosis, viral restriction, and cell cycle control, through the induction of ISG expression.



**Fig 5. Evolution of the ISG-associated functional signature during infection.** Functional enrichment of ISGs differentially expressed at either (A) D9 p.i., (B) M3 p.i., or (C) both time points (D9&M3), was performed using IPA. The right-tailed Fisher Exact Test with the Benjamini-Hochberg correction for multiple tests was used to identify processes showing statistically significant over-representation of focus ISGs. Over-represented functional or pathway processes have more focus genes than expected by chance and the  $-\log(p\text{-values})$  of the most significant functions are plotted in the radar plot.

<https://doi.org/10.1371/journal.pone.0190334.g005>



**Fig 6. Heat-map signatures of differentially expressed ISGs.** The differentially expressed genes of the ISG cluster with the most significant functions are represented as heat-maps. The color intensity shown at each time point is related to the FC in RNA expression: grey for not differentially expressed (not DEG), yellow for FC values between 1 and 2, orange for FC values between 2 and 5, and red for FC values above 5.

<https://doi.org/10.1371/journal.pone.0190334.g006>

IFNs strongly up-regulated the STAT and IRF family transcription factors involved in IFN signaling (**Fig 6-IFN signaling**). Among these, *IFN- $\gamma$* , which is an ISG induced by type I IFN, had a mean FC of 36 during the acute phase, which persisted at six-fold in the chronic phase, when induction of type I IFN expression was not detectable. The three components of ISGF3 (STAT1, STAT2, and IRF9) were also strongly induced in the acute phase and persisted during the chronic phase. NMI, which interacts with all STATs, except STAT2, and augments STAT-mediated transcription in response to *IFN- $\gamma$* , was also induced. The persistence of IRF9, which was confirmed by PCR, may enhance the formation and prolonged presence of ISGF3, which would explain the sustained expression of ISRE-ISG, despite low type I IFN expression during the chronic phase. Overall, these IFN signaling genes may contribute to the amplification of IFN production and ISG expression during both the acute and chronic phases.

The most meaningful downstream effect of ISGs induced during both the acute and chronic phase was the antiviral response, including increased expression of well-known antiviral genes: *MX1*, *OAS1*, *OAS2*, *ISG15*, *IFIT* and *TRIM* family genes, and *RSAD2* (tetherin) (**Fig 6-viral restriction**). Many of these genes are known players in HIV restriction and have antiretroviral activity against HIV/SIV [13, 22, 32, 55]. *ISG15* and *RSAD2* were the most highly induced (112 and 129-fold in acute infection, respectively). Most of these interferon inducible antiviral genes were strongly induced in the acute phase. Their expression was sustained in the chronic phase, but at a much lower level.

The chemokine/cytokine genes, *CXCL-9*, *-10*, and *-11*, known to be strongly induced by *IFN- $\gamma$* , were induced during both the acute and chronic phases. They likely play an important role in the recruitment of a large variety of immune cells to inflamed lymph nodes at both phases of infection (**S4 Fig**). The higher expression of *CXCR3*, the common ligand of these CXCL chemokines, during the chronic phase, likely reflects the recruitment of these cells, including activated T cells, and supports the large contribution of *IFN- $\gamma$*  in chronic inflammation, as previously suggested in rhesus macaques [54]. In contrast, the interferon stimulated pro-inflammatory cytokine genes, *IL-6*, *IL-1B*, *IL15*, *IL15-RA*, and anti-inflammatory gene *IL18BP*, were induced only during the acute phase but were not sustained during the chronic phase showing that IFNs may contribute more strongly to inflammation during the acute than chronic phase, while still maintaining cell trafficking in the lymph nodes during the chronic phase through induction by CXCL chemokines. This controlled expression of IFN-induced pro-inflammatory cytokines in the transition from the acute to chronic phase paralleled the reduction of type I IFN expression to undetectable levels and that of type II IFN to chronic levels (lower than acute phase), although we observed persistently high viral replication in PLNs. *CCL3* and *CCR5* expression increased in both phases and may contribute to persistent migration of *CCR5*<sup>+</sup> target cells to the lymph nodes to fuel SIV replication during the chronic phase, sustaining the observed high level of viral replication (**Fig 1D**). Overall, these results show that many ISGs are key players in SIV induced inflammation and cell trafficking in lymph nodes, with notably different patterns during acute and chronic infection, likely due to changes in the ratio of type I IFN to type II IFN expression over time.

Among differentially expressed ISGs, activation markers, both T-cell (*CD38*) and antigen presenting cell markers (*CD70*, *CD80*, *CD86*), were also induced during the acute phase (**Fig 6-activation**), and *CD38* and *CD70* (*CD27* ligand) expression persisted during the chronic phase, likely related to the chronic T-cell activation that occurs in this model [25].

Strong IFN production during acute infection was also associated with increased expression of numerous pro-apoptotic ISGs (**Fig 6-apoptosis**). Most were strongly induced during the acute phase, but their expression during the chronic phase was much lower and restricted to a few genes. These data suggest that IFNs strongly contribute to the regulation of apoptosis in PLNs both during both primary infection and the chronic phase.

The heat map for cell cycle-ISGs (**Fig 6-cell cycle**) show that the acute phase of SIV infection, which was associated with high type I IFN expression in PLN, was associated with increased expression of anti-proliferative ISGs, such as *GADD45B*, *CDKN2B*, and *NBN*, which act at different points to block the cell cycle. In contrast, ISGs induced exclusively during the chronic phase were most strongly associated with processes related to the G1 phase, genes involved in DNA replication and control, and G1/S and G2/M phase transitions. This set of ISGs included *CDK1*, a cyclin-dependent kinase, *CCNE1*, *MCM7*, *NEK2*, *CDCA8*, *CENPE*, *CENPH*, and *CENPA*. This expression profile, including expression of these cyclins and CDK genes, was specific to the chronic phase, and thus associated with persistent IFN- $\gamma$  expression and undetectable type I IFN expression, suggesting a positive role of IFN- $\gamma$  on the cell cycle.

## Discussion

Chronic expression of ISGs is characteristic of pathogenic SIV/HIV infections [28–30], but the respective contribution of IFN species to the induction of ISG expression is unclear.

The aim of the present study was to discriminate the role of type I and type II IFNs in shaping the pattern of ISG expression over time, and to study the dynamics of biological functions downstream of ISG expression during the acute-to-chronic transition during SIV infection to better understand their role in pathogenesis and immune regulation. We performed a comprehensive analysis of differentially expressed ISGs by microarray in PLNs of SIV infected monkeys. We considered the relative expression changes, the ability to be induced by type I and/or type II IFNs, and the existence of IFN-signaling motifs in the promoter (ISRE and GAS) of each differentially expressed ISG. In parallel, we monitored IFN expression to correlate ISG and IFN expression patterns.

High expression of both type I and type II IFNs in PLNs, during the acute phase of infection, switched to persistent IFN- $\gamma$  expression and type I IFN expression below the threshold of detection during the chronic phase. This observation is in accordance with other models of pathogenic SIV infection [53, 56]. Our results clearly show that IFN- $\alpha$ , IFN- $\beta$ , IFN- $\omega$ , and IFN- $\gamma$  were strongly expressed in PLNs, to a lesser extent in RB (with high inter-individual variation), and not in PBMCs, in accordance with the finding of Abel *et al.* [32, 54]. These data highlight lymph nodes as a major source of IFNs during primary infection. Our data contrast with previously published microarray studies in which type I IFNs were not detected by microarrays in either blood, PBMCs, blood CD4 T cells, or PLN cells in pathogenic models [28–30]. This may be due to differences in the time of sampling after infection, sensitivity of the microarrays used, or the type of tissue analyzed. Indeed, our choice of sampling PLNs at the peak of type I IFN levels in plasma, based on our knowledge of the model and the early cytokine burst in HIV-infection [25, 34], was critical, as type I IFN was only consistently detectable in PLNs during the early phase of primary infection. Use of the Agilent macaque DNA array platform, which offers both a high dynamic range of gene expression measurements and high sensitivity, was also likely critical for measuring the expression of type I IFN genes. Indeed, microarray and RT-qPCR measurements in PLN were positively correlated ( $p < 0.0001$ ,  $r = 0.9881$  for IFN- $\alpha$ ;  $p = 0.0003$ ,  $r = 0.8639$  for IFN- $\gamma$ ).

Changes of IFN expression patterns over time were associated with the evolution of the ISG expression pattern. During the acute phase of infection, we observed 220 differentially

expressed ISGs, in accordance with pioneering work in other pathogenic models [28–30], which showed strong IFN responses to primary SIV infections. Our work is original because we concentrated our analysis on the origin of ISG expression. We identified three classes of ISGs, type I-ISGs (inducible only by type I IFNs), type II-ISGs (inducible only by type II IFNs), and type I&II-ISGs (inducible by both type I and type II IFNs), which were the most abundant. Fewer ISGs were expressed during the chronic phase than in the acute phase of infection, but we observed a similar distribution pattern for these three classes at the latter time point (type I&II-ISGs > type I-ISGs > type II-ISGs). The transition from acute-to-chronic infection was also associated with changes in the functional pattern of differentially expressed ISGs, and a decrease of their expression. Indeed, ISGs induced during the acute phase were either expressed at lower levels during the chronic phase, or not at all. However, some ISGs most strongly involved in cell cycle control and mitosis were induced exclusively during the chronic phase. These data support the conclusion that both type I IFNs and IFN- $\gamma$  specifically imprint the ISG expression pattern during both phases of infection (type I-ISGs and type II-ISGs, respectively) and suggest that convergence of type I and type II IFNs is important during both phases of pathogenic SIV infection for sustained expression of the large set of type I&II ISGs at higher levels than either type I or type II-ISGs. These data suggest that persistent expression of a large array of ISGs during the chronic phase could be largely due to IFN- $\gamma$ , fueled by chronic T-cell activation [6, 57, 58], and NK cells [59]. Indeed, the expression of several well-known IFN $\gamma$ -inducible ISGs, such as Mig (*CXCL9*) and IP-10 (*CXCL10*) were sustained during the chronic phase in PLNs. The parallel increase in the expression of their receptor, CXCR3, is consistent with a previous report on rhesus macaques, suggesting that IFN- $\gamma$  induced Mig/*CXCL9* and IP-10/*CXCL10* expression results in the recruitment of CXCR3<sup>+</sup>-activated T cells, promoting SIV replication and persistent inflammation [54].

The finding that 13 ISGs, differentially expressed during the chronic phase, harbor an ISRE but no GAS in their promoters (S5 Fig), suggests possible induction by the ISGF3/ISRE canonical type I pathway, or by non-canonical type II IFN signaling. Alternatively, these genes could be induced by other transcriptional factors [19, 60], independently of IFN. Several studies demonstrated ISGF3 complex alternative activation following IFN- $\gamma$  treatment in murine cells [61], suggesting a role for ISGF3 in the convergence and synergy of type I and type II IFN signaling. ISGF3 can induce expression of type II IFN, which is a type I inducible gene, amplifying further the response to type I IFN. We observed a persistence of expression of both STAT1 and IRF9 during the chronic phase of infection, albeit at lower levels. Type I IFN expression was not detectable during the chronic phase, in contrast to IFN- $\gamma$ . Thus, these data suggest that type II IFN may contribute to STAT1 and IRF9 expression and the formation and prolonged persistence of ISGF3 to target ISRE harboring ISGs. Based on these observations, we propose that chronic IFN- $\gamma$  induction could contribute to induce the expression of ISRE harboring genes through ISGF3 signaling. Indeed, in our study, two genes, which are only type II IFN inducible, fit this paradigm, as they were expressed during the chronic phase, suggesting that there is such an alternative pathway *in vivo*, as reported *in vitro* [61]. However, their incidence is probably low, as all other type II IFN-inducible ISGs bear GAS (S5 Fig).

Our data also suggest that alternative type I IFN signaling takes place *in vivo*. Type I IFN can induce canonical type II IFN-signaling molecules through the induction of active STAT1 homodimers, which can bind to GAS sites to activate the transcription of target genes [62]. In our study, 13 and 11 genes differentially expressed during the acute or chronic phase, respectively, fit this paradigm, as they are only inducible by type I IFNs but harbor only GAS and not ISRE in their promoters (S5 Fig).

Type I and type II IFN signaling pathways crosstalk at other levels and can activate distinct and common ISGs that govern their antiviral effects. Most responses to type I and type II IFNs

require the STAT1 transcription factor [63]. In our model, differential STAT1 expression at both phases of infection could be a possible point of synergy between type I and type II IFNs. Our DNA array study in lymphatic tissue also revealed phase-specific IFN-induced gene expression and highlights the role of type I and type II interferons in the antiviral response to SIV infection and their contribution to numerous biological functions. The interferon response plays an important role in innate immunity against viruses [64]. The strong and early IFN signaling observed here is consistent with reports suggesting that a strong innate immune response in lymph nodes is a mechanism for limiting SIV pathogenesis [65]. It was previously shown that IFNs can block SIV replication at early phases of infection *in vitro* [66, 67]. Although type I and type II IFNs likely inhibit viral replication and activate anti-viral immune responses, these responses are not sufficient to prevent chronic infection. The ineffectiveness of the IFN response in containing viral infection could result from insufficient production of most efficient cytokines [68] or viral resistance to IFNs during infection. Our analysis suggests that type I IFN synergizes with type II IFN early to induce anti-viral and restriction factors that may help to limit viral replication *in vivo*, although the absence of genotyping of restriction factors in our study is a clear limit in our interpretation of expression data. Blocking type I IFN signaling early in infection was recently shown to worsen SIV infection [69]. The early IFN response could thus participate in the selection of type I IFN-resistant variants, as observed in HIV primary infection [35]. Lower type I IFN expression during the chronic phase, likely responsible for the observed reduced levels and repertoire of restriction factors in our study, may release viral progeny from IFN pressure. Indeed, viral isolates obtained during the chronic phase of HIV infection are less resistant than viruses isolated during primary infection early after the acute IFN response [35].

Several differentially expressed ISGs encode cytokines, chemokines, and their receptors, involved in inflammation and cell recruitment to inflamed lymph nodes. Primary infection was characterized by a burst of expression of IFNs and IFN-induced pro-inflammatory cytokines (IL-1b, IL-6, IL-15 and IFN- $\gamma$ ), chemokines (CXCL9,10,11, CCL3, 8, 11, 28), and IFN-induced chemokine receptors (CCR1, CCR5, CXCR3), whereas this pattern was reduced to IFN- $\gamma$  in the chronic phase, despite persistent viral replication in the PLNs. Although most of these genes are also inducible by other factors [70, 71], most are inducible by both type I IFNs and type II IFN. This suggests that high type I IFN and type II IFN expression during primary infection synergize to take part in inflammation in lymph nodes, creating a favorable milieu for immune cell recruitment. During the chronic phase, in a much lower pro-inflammatory context, including undetectable type I IFN, IFN- $\gamma$  likely remains one of the few major actors of inflammation and cell recruitment in lymph nodes. Indeed, persistent high IFN- $\gamma$  expression was associated with persistent expression of IFN- $\gamma$  inducible CXCR3 ligands, including CXCL9,10,11, which may contribute to the recruitment of immune cells, such as pDC, which persistently accumulate in lymph nodes during chronic SIV infection in our model [25, 31], express CXCR3 and CCR5 [72], and respond to CXCR3 ligands [73]. Activation of pDC in lymph nodes [25] may also contribute to CCL3 expression, further increasing the attraction of pDCs and other CCR5<sup>+</sup> cells. Increased expression of CCL3 may be a beneficial response of the host against HIV/SIV infection, due to its ability to block HIV entry into CCR5<sup>+</sup> T cells [74], but it can also be deleterious, through the recruitment of new target cells to inflamed lymph nodes. The CCL3 gene is reported to be type I IFN-inducible in the Interferome database. However, it bears a GAS sequence, but no ISRE, in its promoter and could thus be sustained by IFN- $\gamma$  during the chronic phase or low undetectable type I IFN expression through alternative type I IFN signaling.

We observed a significant decline in the number of CD4 T cells, a signature of SIV and HIV pathogenesis that drives disease progression [75], below baseline levels. The pathway causing CD4 T-cell death in HIV-infected hosts is poorly understood [76], but may involve IFN

responses. Most (95%) quiescent lymphoid CD4 T cells die by caspase-1-mediated pyroptosis, a highly inflammatory form of programmed cell death [77]. Our study highlights the significant differential expression of several mediators of pyroptosis, such as IL1- $\beta$ , Casp1, NLRP3, and IL15 during acute infection and the absence of induction of Casp3 expression. The involvement of IFNs in pyroptosis could therefore contribute to the early depletion of CD4 T cells in lymph nodes and other tissues. These pyroptosis mediators were barely detectable during the chronic phase, when type I IFN was also undetectable, and two of them (Casp1 and NLRP3) are GAS activated genes whereas IL-15 and IL1b are GAS&ISRE ISGs, suggesting IFN- $\gamma$  may play a more important role than type I IFN. In non-pathogenic SIV infections, Casp3-dependent apoptosis of productively infected cells may be responsible for most cell death rather than that mediated by Casp1, thus avoiding local inflammation [78].

IFNs are known for their anti-proliferative effects [12, 79]. Our data show that during the acute phase of SIV infection, differentially expressed ISGs involved in the cell cycle included more anti-proliferative genes (CDKN2B, NBN, GAB45B) which act at different phases to block the cell cycle, than during the chronic phase (CDKN3). Indeed, during the chronic phase, cell cycle-associated ISGs were more strongly associated with functions/mechanisms that support progression through the cell cycle. This is in accordance with the reported synergy between IFN- $\alpha$  and IFN- $\gamma$  to promote anti-proliferative effects [80], and suggests that coordinated expression of IFN- $\alpha$  and IFN- $\gamma$  during the peak of IFN- $\alpha$  production in primary infection may transiently delay immune cell expansion. Indeed, lower numbers of proliferative T and B cells were previously found in PLNs at day 8 or 11 than at day15 p.i. in this model [50], when type I and type II IFN production is already much lower. Our data suggest that when type I IFN falls to undetectable levels, persistent type II IFN production during the chronic phase results in the induction of a specific set of ISGs likely more favorable for the division of immune cells. We previously reported that cycling T cells increased after day 14 p.i. in PLNs and blood in our model [50], when type I IFN-I had already dropped to low levels [31]. This paradigm is also supported by data reported in mice showing that IFN- $\gamma$  increases the entry of lymph node CD4<sup>+</sup> T cells into the cell cycle, favoring cell expansion [81]. Persistent IFN- $\gamma$  expression could therefore facilitate T-cell cycling through the induction of phase-specific ISGs during the chronic phase, when levels of anti-proliferative ISGs (CDKN2B, NBN, GAB45B), associated with type I IFN expression, have dropped. Overall, our data suggests that the balance between type I and type II IFN levels is important in regulating the cell cycle during the different phases of infection.

In conclusion, this global analysis, focusing on type I and type II ISG expression patterns, revealed that most differentially expressed ISGs are inducible by both type I and type II IFNs. ISG induced by both type I and type II IFNs were the most highly induced, suggesting that both IFN types converge and synergize to promote many biological functions. This phase-specific ISG response likely results from the switch from a type I to type II IFN-dominated ratio and highlights the significance of IFN- $\gamma$  in shaping ISG response during the chronic phase. Although these genes could also be co-regulated by other transcriptional factors, a potential confounding and limiting factor in our study, the identification of phase-specific IFN-regulated genes advances our knowledge of the complex role of IFN species in HIV/SIV pathogenesis, which may pave the way to improve therapeutics that target specific host or virally-induced IFN pathways.

## Supporting information

### S1 Fig. ISG annotations.

(PDF)

### S2 Fig. Functional enrichment of differentially expressed genes.

(PDF)

**S3 Fig. Comparison of the extent of IFNs and selected ISG expression in both phases of infection in RB, PLNs, and PBMCs.**

(PDF)

**S4 Fig. The main IPA functions associated with D9-ISGs and M3-ISGs.**

(PDF)

**S5 Fig. Overlap between Interferome annotation and GAS/ISRE annotation of differentially induced ISGs.**

(PDF)

**S1 Table. primers and probes.**

(XLSX)

**S2 Table. Functional enrichment analysis of PLNs, RBs, and PBMCs at D9 and M3.**

(XLSX)

**S3 Table. List of ISGs differentially expressed at either D9, M3, or both time points with their mean FC and associated functions.**

(XLSX)

## Acknowledgments

The authors thank Hybrigenics-Helixio (former Imaxio) to which the microarrays were sub-contracted for technical advice, quality controls of RNA samples, microarrays, and initial statistical analysis. The authors are particularly thankful to Véronique VIDAL and Valérie CHABAUD from HELIXIO, for their efficiency and technical advices.

## Author Contributions

**Conceptualization:** Bruno Vaslin.

**Data curation:** Nadia Echebli, Nicolas Tchitckek, Nathalie Bosquet, Rémi Cheynier.

**Formal analysis:** Nadia Echebli, Nicolas Tchitckek, Nathalie Bosquet, Rémi Cheynier, Bruno Vaslin.

**Funding acquisition:** Roger Le Grand, Bruno Vaslin.

**Investigation:** Nadia Echebli, Stéphanie Dupuy, Timothée Buel.

**Methodology:** Nadia Echebli, Nicolas Tchitckek, Stéphanie Dupuy, Timothée Buel, Caroline Peireira Bittencourt Passaes, Nathalie Bosquet, Rémi Cheynier.

**Resources:** Rémi Cheynier.

**Software:** Nicolas Tchitckek.

**Supervision:** Bruno Vaslin.

**Visualization:** Nadia Echebli.

**Writing – original draft:** Nadia Echebli, Nicolas Tchitckek, Bruno Vaslin.

**Writing – review & editing:** Timothée Buel, Caroline Peireira Bittencourt Passaes, Roger Le Grand, Christine Bourgeois, Benoit Favier, Rémi Cheynier, Olivier Lambotte, Bruno Vaslin.

## References

1. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. *The Journal of biological chemistry*. 2007; 282(28):20047–51. <https://doi.org/10.1074/jbc.R700004200> PMID: [17502369](#).
2. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. *Immunological reviews*. 2004; 202:8–32. <https://doi.org/10.1111/j.0105-2896.2004.00204.x> PMID: [15546383](#).
3. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. *Annual review of immunology*. 2014; 32:513–45. <https://doi.org/10.1146/annurev-immunol-032713-120231> PMID: [24555472](#).
4. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. *Proc Natl Acad Sci U S A*. 1998; 95(26):15623–8. PMID: [9861020](#); PubMed Central PMCID: [PMCPMC28094](#).
5. Decker T, Stockinger S, Karaghiosoff M, Muller M, Kovarik P. IFNs and STATs in innate immunity to microorganisms. *J Clin Invest*. 2002; 109(10):1271–7. <https://doi.org/10.1172/JCI15770> ISI:000175760100002. PMID: [12021240](#)
6. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. *Nat Med*. 2013; 19(7):859–68. <https://doi.org/10.1038/nm.3251> ISI:000321557700029. PMID: [23836236](#)
7. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, et al. Interferon signaling and treatment outcome in chronic hepatitis C. *Proc Natl Acad Sci U S A*. 2008; 105(19):7034–9. <https://doi.org/10.1073/pnas.0707882105> PMID: [18467494](#); PubMed Central PMCID: [PMCPMC2383932](#).
8. Isaacs A, Lindenmann J. Virus interference. I. The interferon. *Proc R Soc Lond B Biol Sci*. 1957; 147(927):258–67. PMID: [13465720](#).
9. Samuel CE. Antiviral actions of interferons. *Clinical microbiology reviews*. 2001; 14:778–809, table of contents. <https://doi.org/10.1128/CMR.14.4.778-809.2001> PMID: [11585785](#).
10. Hubbard JJ, Greenwell-Wild T, Barrett L, Yang J, Lempicki RA, Wahl SM, et al. Host gene expression changes correlating with anti-HIV-1 effects in human subjects after treatment with peginterferon Alfa-2a. *The Journal of infectious diseases*. 2012; 205:1443–7. <https://doi.org/10.1093/infdis/jis211> PMID: [22454462](#).
11. de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, et al. Functional classification of interferon-stimulated genes identified using microarrays. *J Leukoc Biol*. 2001; 69(6):912–20. PMID: [11404376](#).
12. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. *Apoptosis: an international journal on programmed cell death*. 2003; 8(3):237–49. Epub 2003/05/27. PMID: [12766484](#).
13. Kane M, Zang TM, Rihn SJ, Zhang F, Kueck T, Alim M, et al. Identification of Interferon-Stimulated Genes with Antiretroviral Activity. *Cell host & microbe*. 2016; 20(3):392–405. Epub 2016/09/16. <https://doi.org/10.1016/j.chom.2016.08.005> PMID: [27631702](#); PubMed Central PMCID: [PMC5026698](#).
14. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. *Nature reviews Immunology*. 2012; 12(2):125–35. <https://doi.org/10.1038/nri3133> PMID: [22222875](#); PubMed Central PMCID: [PMCPMC3727154](#).
15. Chang JJ, Altfeld M. Innate Immune Activation in Primary HIV-1 Infection. *J Infect Dis*. 2010; 202:S297–S301. <https://doi.org/10.1086/655657> ISI:000281911000005. PMID: [20846036](#)
16. Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. *J Hepatol*. 2014; 61: S14–S25. ISI:000345115800003. <https://doi.org/10.1016/j.jhep.2014.06.035> PMID: [25443342](#)
17. Rauch I, Muller M, Decker T. The regulation of inflammation by interferons and their STATs. *JAKSTAT*. 2013; 2(1):e23820. <https://doi.org/10.4161/jkst.23820> PMID: [24058799](#); PubMed Central PMCID: [PMCPMC3670275](#).
18. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. *J Leukoc Biol*. 2004; 75(2):163–89. <https://doi.org/10.1189/jlb.0603252> PMID: [14525967](#).
19. Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector functions. *Current opinion in virology*. 2011; 1(6):519–25. Epub 2012/02/14. <https://doi.org/10.1016/j.coviro.2011.10.008> PMID: [22328912](#); PubMed Central PMCID: [PMC3274382](#).
20. Paludan SR. Innate Antiviral Defenses Independent of Inducible IFN $\alpha$ / $\beta$  Production. *Trends in Immunology*. 2016; 37:588–96. <https://doi.org/10.1016/j.it.2016.06.003> PMID: [27345728](#)

21. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, et al. Glycerol monolaurate prevents mucosal SIV transmission. *Nature*. 2009; 458(7241):1034–8. <https://doi.org/10.1038/nature07831> PMID: 19262509; PubMed Central PMCID: PMCPMC2785041.
22. Sandler NG, Bosinger SE, Estes JD, Zhu RT, Tharp GK, Boritz E, et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. *Nature*. 2014; 511(7511):601–5. Epub 2014/07/22. <https://doi.org/10.1038/nature13554> PMID: 25043006; PubMed Central PMCID: PMC4418221.
23. Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. *J clin invest*. 2005; 115(11):3265–75. Epub 2005/10/15. <https://doi.org/10.1172/JCI26032> PMID: 16224540; PubMed Central PMCID: PMC1253628.
24. Lepelley A, Louis S, Sourisseau M, Law HK, Pothlichet J, Schilte C, et al. Innate sensing of HIV-infected cells. *PLoS pathogens*. 2011; 7(2):e1001284. <https://doi.org/10.1371/journal.ppat.1001284> PMID: 21379343; PubMed Central PMCID: PMCPMC3040675.
25. Bruel T, Dupuy S, Démoulin T, Rogez-Kreuz C, Dutrieux J, Corneau A, et al. Plasmacytoid Dendritic Cell Dynamics Tune Interferon-Alpha Production in SIV-Infected Cynomolgus Macaques. *PLoS pathogens*. 2014; 10:e1003915. <https://doi.org/10.1371/journal.ppat.1003915> PMID: 24497833
26. Harris LD, Tabb B, Sodora DL, Paiardini M, Klatt NR, Douek DC, et al. Downregulation of Robust Acute Type I Interferon Responses Distinguishes Nonpathogenic Simian Immunodeficiency Virus (SIV) Infection of Natural Hosts from Pathogenic SIV Infection of Rhesus Macaques. *J Virol*. 2010; 84(15):7886–91. <https://doi.org/10.1128/JVI.02612-09> ISI:000279989800046. PMID: 20484518
27. O'Brien M, Manches O, Bhardwaj N. Plasmacytoid dendritic cells in HIV infection. *Advances in experimental medicine and biology*. 2013; 762:71–107. Epub 2012/09/15. [https://doi.org/10.1007/978-1-4614-4433-6\\_3](https://doi.org/10.1007/978-1-4614-4433-6_3) PMID: 22975872; PubMed Central PMCID: PMC3713461.
28. Jacquelin B, Mayau V, Targat B, Liovat AS, Kunkel D, Petitjean G, et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. *J clin invest*. 2009; 119(12):3544–55. Epub 2009/12/05. <https://doi.org/10.1172/JCI40093> PMID: 19959873; PubMed Central PMCID: PMC2786805.
29. Bosinger SE, Li Q, Gordon SN, Klatt NR, Duan L, Xu L, et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. *J clin invest*. 2009; 119(12):3556–72. Epub 2009/12/05. <https://doi.org/10.1172/JCI40115> PMID: 19959874; PubMed Central PMCID: PMC2786806.
30. Lederer S, Favre D, Walters KA, Proll S, Kanwar B, Kasakow Z, et al. Transcriptional profiling in pathogenic and non-pathogenic SIV infections reveals significant distinctions in kinetics and tissue compartmentalization. *PLoS pathogens*. 2009; 5(2):e1000296. Epub 2009/02/14. <https://doi.org/10.1371/journal.ppat.1000296> PMID: 19214219; PubMed Central PMCID: PMC2633618.
31. Malleret B, Maneglier B, Karlsson I, Lebon P, Nascimbeni M, Perie L, et al. Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. *Blood*. 2008; 112(12):4598–608. Epub 2008/09/13. <https://doi.org/10.1182/blood-2008-06-162651> PMID: 18787223.
32. Abel K, Alegria-Hartman MJ, Rothaeusler K, Marthas M, Miller CJ. The relationship between simian immunodeficiency virus RNA levels and the mRNA levels of alpha/beta interferons (IFN-alpha/beta) and IFN-alpha/beta-inducible Mx in lymphoid tissues of rhesus macaques during acute and chronic infection. *Journal of virology*. 2002; 76:8433–45. <https://doi.org/10.1128/JVI.76.16.8433-8445.2002> PMID: 12134046.
33. Neil S, Bieniasz P. Human immunodeficiency virus, restriction factors, and interferon. *Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research*. 2009; 29(9):569–80. Epub 2009/08/22. <https://doi.org/10.1089/jir.2009.0077> PMID: 19694548; PubMed Central PMCID: PMC2956573.
34. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. *Journal of virology*. 2009; 83(8):3719–33. Epub 2009/01/30. <https://doi.org/10.1128/JVI.01844-08> PMID: 19176632; PubMed Central PMCID: PMC2663284.
35. Fenton-May AE, Dibben O, Emmerich T, Ding H, Pfafferoth K, Aasa-Chapman MM, et al. Relative resistance of HIV-1 founder viruses to control by interferon-alpha. *Retrovirology*. 2013; 10:146. Epub 2013/12/05. <https://doi.org/10.1186/1742-4690-10-146> PMID: 24299076; PubMed Central PMCID: PMC3907080.
36. Doyle T, Goujon C, Malim MH. HIV-1 and interferons: who's interfering with whom? *Nature reviews Microbiology*. 2015; 13(7):403–13. Epub 2015/04/29. <https://doi.org/10.1038/nrmicro3449> PMID: 25915633.

37. Zhen A, Rezek V, Youn C, Lam B, Chang N, Rick J, et al. Targeting type I interferon-mediated activation restores immune function in chronic HIV infection. *Journal of Clinical Investigation*. 2017; 127(1):260–8. <https://doi.org/10.1172/JCI89488> ISI:000392271300026. PMID: 27941243
38. Roff SR, Noon-Song EN, Yamamoto JK. The significance of interferon-gamma in HIV-1 pathogenesis, therapy, and prophylaxis. *Front Immunol*. 2014; 4: Artn 498 <https://doi.org/10.3389/Fimmu.2013.00498> ISI:000354032100001.
39. Liovat AS, Rey-Cuille MA, Lecuroux C, Jacquelin B, Girault I, Petitjean G, et al. Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection. *PloS one*. 2012; 7(10):e46143. Epub 2012/10/12. <https://doi.org/10.1371/journal.pone.0046143> PMID: 23056251; PubMed Central PMCID: PMC3462744.
40. Ploquin MJ, Madec Y, Casrouge A, Huot N, Passaes C, Lecuroux C, et al. Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset. *PLoS pathogens*. 2016; 12(8). ARTN e1005774 <https://doi.org/10.1371/journal.ppat.1005774> ISI:000383376000019.
41. Roberts L, Passmore JA, Williamson C, Little F, Bebell LM, Misana K, et al. Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. *AIDS*. 2010; 24(6):819–31. Epub 2010/03/13. <https://doi.org/10.1097/QAD.0b013e3283367836> PMID: 20224308; PubMed Central PMCID: PMC3001189.
42. Fink K, Grandvaux N. STAT2 and IRF9: Beyond ISGF3. *JAK-STAT*. 2013; 2:e27521. <https://doi.org/10.4161/jkst.27521> PMID: 24498542.
43. Blaszczyk K, Olejnik A, Nowicka H, Ozgyin L, Chen YL, Chmielewski S, et al. STAT2/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1. *The Biochemical journal*. 2015; 466(3):511–24. Epub 2015/01/08. <https://doi.org/10.1042/BJ20140644> PMID: 25564224; PubMed Central PMCID: PMC4403947.
44. Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor signaling. *Annual review of immunology*. 1997; 15:563–91. <https://doi.org/10.1146/annurev.immunol.15.1.563> PMID: 9143700.
45. Wang W, Xu L, Su J, Peppelenbosch MP, Pan Q. Transcriptional Regulation of Antiviral Interferon-Stimulated Genes. *Trends in microbiology*. 2017. Epub 2017/02/01. <https://doi.org/10.1016/j.tim.2017.01.001> PMID: 28139375.
46. Majoros A, Platanitis E, Kernbauer-Hözl E, Rosebrock F, Müller M, Decker T. Canonical and Non-Canonical Aspects of JAK-STAT Signaling: Lessons from Interferons for Cytokine Responses. *Front Immunol*. 2017; 8:29. <https://doi.org/10.3389/fimmu.2017.00029> PMID: 28184222.
47. Lackmann M, Harpur AG, Oates AC, Mann RJ, Gabriel A, Meutermans W, et al. Biomolecular interaction analysis of IFN gamma-induced signaling events in whole-cell lysates: prevalence of latent STAT1 in high-molecular weight complexes. *Growth factors (Chur, Switzerland)*. 1998; 16:39–51. PMID: 9777369.
48. Rusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H, et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. *Nucleic acids research*. 2013; 41(Database issue): D1040–6. <https://doi.org/10.1093/nar/gks1215> PMID: 23203888; PubMed Central PMCID: PMC3531205.
49. Karlsson I, Malleret B, Brochard P, Delache B, Calvo J, Le Grand R, et al. FoxP3+ CD25+ CD8+ T-cell induction during primary simian immunodeficiency virus infection in cynomolgus macaques correlates with low CD4+ T-cell activation and high viral load. *Journal of virology*. 2007; 81:13444–55. <https://doi.org/10.1128/JVI.01466-07> PMID: 17898053.
50. Benlhassan-Chahour K, Penit C, Dioszeghy V, Vasseur F, Janvier G, Riviere Y, et al. Kinetics of lymphocyte proliferation during primary immune response in macaques infected with pathogenic simian immunodeficiency virus SIVmac251: Preliminary report of the effect of early antiviral therapy. *Journal of virology*. 2003; 77(23):12479–93. <https://doi.org/10.1128/JVI.77.23.12479-12493.2003> ISI:000186612700011. PMID: 14610172
51. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic acids research*. 2001; 29(9):e45. Epub 2001/05/09. PMID: 11328886; PubMed Central PMCID: PMC55695.
52. Dutriex J, Fabre-Mersseman V, Charmeteau-De Muyllder B, Rancez M, Ponte R, Rozlan S, et al. Modified interferon-alpha subtypes production and chemokine networks in the thymus during acute simian immunodeficiency virus infection, impact on thymopoiesis. *AIDS*. 2014; 28(8):1101–13. <https://doi.org/10.1097/QAD.000000000000249> PMID: 24614087.
53. Abel K, Rocke DM, Chohan B, Fritts L, Miller CJ. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. *J Virol*. 2005; 79(19):12164–72. <https://doi.org/10.1128/JVI.79.19.12164-12172.2005> PMID: 16160143; PubMed Central PMCID: PMC1211549.

54. Abel K, La Franco-Scheuch L, Rourke T, Ma Z-M, De Silva V, Fallert B, et al. Gamma interferon-mediated inflammation is associated with lack of protection from intravaginal simian immunodeficiency virus SIVmac239 challenge in simian-human immunodeficiency virus 89.6-immunized rhesus macaques. *Journal of virology*. 2004; 78:841–54. <https://doi.org/10.1128/JVI.78.2.841-854.2004> PMID: 14694116.
55. Borrow P. Innate immunity in acute HIV-1 infection. *Current opinion in HIV and AIDS*. 2011; 6(5):353–63. Epub 2011/07/08. <https://doi.org/10.1097/COH.0b013e3283495996> PMID: 21734567; PubMed Central PMCID: PMC3266478.
56. Khatissian E, Chakrabarti L, Hurtrel B. Cytokine patterns and viral load in lymph nodes during the early stages of SIV infection. *Research in virology*. 1996; 147(2–3):181–9. Epub 1996/03/01. PMID: 8901438.
57. Cha L, de Jong E, French MA, Fernandez S. IFN-alpha exerts opposing effects on activation-induced and IL-7-induced proliferation of T cells that may impair homeostatic maintenance of CD4+ T cell numbers in treated HIV infection. *J Immunol*. 2014; 193(5):2178–86. <https://doi.org/10.4049/jimmunol.1302536> PMID: 25063872.
58. Zuniga EI, Macal M, Lewis GM, Harker JA. Innate and Adaptive Immune Regulation During Chronic Viral Infections. *Ann Rev Virol*. 2015; 2:573–97. <https://doi.org/10.1146/annurev-virology-100114-055226> ISI:000364397900026. PMID: 26958929
59. Jacquelin B, Petitjean G, Kunkel D, Liovat AS, Jochems SP, Rogers KA, et al. Innate Immune Responses and Rapid Control of Inflammation in African Green Monkeys Treated or Not with Interferon-Alpha during Primary SIVagm Infection. *PLoS pathogens*. 2014; 10(7). ARTN e1004241 <https://doi.org/10.1371/journal.ppat.1004241> ISI:000340551000032.
60. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. *Nature Reviews Immunology*. 2014; 14(1):36–49. <https://doi.org/10.1038/nri3581> ISI:000328962200012. PMID: 24362405
61. Morrow AN, Schmeisser H, Tsuno T, Zoon KC. A Novel Role for IFN-Stimulated Gene Factor 3(II) in IFN-gamma Signaling and Induction of Antiviral Activity in Human Cells. *Journal of Immunology*. 2011; 186(3):1685–93. <https://doi.org/10.4049/jimmunol.1001359> ISI:000286381200048. PMID: 21178011
62. Platanius LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. *Nature Reviews Immunology*. 2005; 5(5):375–86. <https://doi.org/10.1038/nri1604> ISI:000228833700012. PMID: 15864272
63. Beutler B, Crozat K, Koziol JA, Georgel P. Genetic dissection of innate immunity to infection: the mouse cytomegalovirus model. *Curr Opin Immunol*. 2005; 17(1):36–43. <https://doi.org/10.1016/j.coi.2004.11.004> ISI:000226769500007. PMID: 15653308
64. Wong MT, Chen SSL. Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection. *Cell Mol Immunol*. 2016; 13(1):11–35. <https://doi.org/10.1038/cmi.2014.127> ISI:000371996300003. PMID: 25544499
65. Pereira LE, Johnson RP, Ansari AA. Sooty mangabeys and rhesus macaques exhibit significant divergent natural killer cell responses during both acute and chronic phases of SIV infection. *Cellular immunology*. 2008; 254:10–9. <https://doi.org/10.1016/j.cellimm.2008.06.006> PMID: 18640666.
66. Taylor MD, Korth MJ, Katze MG. Interferon treatment inhibits the replication of simian immunodeficiency virus at an early stage: evidence for a block between attachment and reverse transcription. *Virology*. 1998; 241:156–62. <https://doi.org/10.1006/viro.1997.8964> PMID: 9454726.
67. Borrow P, Shattock RJ, Vyakarnam A, Grp EW. Innate immunity against HIV: a priority target for HIV prevention research. *Retrovirology*. 2010; 7. ArtN 84 <https://doi.org/10.1186/1742-4690-7-84> ISI:000283419200001.
68. Gibbert K, Schlaak JF, Yang D, Dittmer U. IFN- subtypes: distinct biological activities in anti-viral therapy. *Brit J Pharmacol*. 2013; 168(5):1048–58. <https://doi.org/10.1111/bph.12010> ISI:000315299700002. PMID: 23072338
69. Cheng L, Ma JP, Li JY, Li D, Li GM, Li F, et al. Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs. *Journal of Clinical Investigation*. 2017; 127(1):269–79. <https://doi.org/10.1172/JCI90745> ISI:000392271300027. PMID: 27941247
70. Beq S, Rozlan S, Gautier D, Parker R, Mersseman V, Schilte C, et al. Injection of glycosylated recombinant simian IL-7 provokes rapid and massive T-cell homing in rhesus macaques. *Blood*. 2009; 114(4):816–25. <https://doi.org/10.1182/blood-2008-11-191288> PMID: 19351957.
71. Ponte R, Rancez M, Figueiredo-Morgado S, Dutrioux J, Fabre-Mersseman V, Charmeteau-de-Muylder B, et al. Acute Simian Immunodeficiency Virus Infection Triggers Early and Transient Interleukin-7 Production in the Gut, Leading to Enhanced Local Chemokine Expression and Intestinal Immune Cell Homing. *Front Immunol*. 2017; 8:588. <https://doi.org/10.3389/fimmu.2017.00588> PMID: 28579989; PubMed Central PMCID: PMC5437214.
72. Penna G, Sozzani S, Adorini L. Cutting edge: Selective usage of chemokine receptors by plasmacytoid dendritic cells. *Journal of Immunology*. 2001; 167(4):1862–6. ISI:000170949600004.

73. Krug A, Uppaluri R, Facchetti F, Dorner BG, Sheehan KCF, Schreiber RD, et al. Cutting edge: IFN-producing cells respond to CXCR3 ligands in the presence of CXCL12 and secrete inflammatory chemokines upon activation. *Journal of Immunology*. 2002; 169(11):6079–83. ISI:000179478400001.
74. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. *Science*. 1995; 270(5243):1811–5. PMID: [8525373](#).
75. Deeks SG. HIV Infection, Inflammation, Immunosenescence, and Aging. *Annu Rev Med*. 2011; 62:141–55. <https://doi.org/10.1146/annurev-med-042909-093756> ISI:000287956900011. PMID: [21090961](#)
76. Thomas C. Roadblocks in HIV research: five questions. *Nat Med*. 2009; 15(8):855–9. <https://doi.org/10.1038/nm0809-855> ISI:000268770400025. PMID: [19661992](#)
77. Eckstein DA, Penn ML, Korin YD, Scripture-Adams DD, Zack JA, Kreisberg JF, et al. HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. *Immunity*. 2001; 15(4):671–82. [https://doi.org/10.1016/S1074-7613\(01\)00217-5](https://doi.org/10.1016/S1074-7613(01)00217-5) ISI:000171757800017. PMID: [11672548](#)
78. Doitsh G, Galloway NLK, Geng X, Yang ZY, Monroe KM, Zepeda O, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. *Nature*. 2014; 505(7484):509–+. <https://doi.org/10.1038/nature12940> ISI:000329995000031. PMID: [24356306](#)
79. Zhao YH, Wang T, Yu GF, Zhuang DM, Zhang Z, Zhang HX, et al. Anti-proliferation Effects of Interferon-gamma on Gastric Cancer Cells. *Asian Pac J Cancer P*. 2013; 14(9):5513–8. <https://doi.org/10.7314/APJCP.2013.14.9.5513> ISI:000328273000096.
80. Schiller JH, Groveman DS, Schmid SM, Willson JKV, Cummings KB, Borden EC. Synergistic Antiproliferative Effects of Human Recombinant Alpha-54-Interferon or Beta-Ser-Interferon with Gamma-Interferon on Human Cell-Lines of Various Histogenesis. *Cancer research*. 1986; 46(2):483–8. ISI: A1986AYB3800004. PMID: [2416427](#)
81. Reed JM, Branigan PJ, Bamezai A. Interferon Gamma Enhances Clonal Expansion and Survival of CD4(+) T Cells. *J Interf Cytok Res*. 2008; 28(10):611–22. <https://doi.org/10.1089/jir.2007.0145> ISI:000260054300004. PMID: [18778202](#)